{"disease":{"id":"relapsing-multiple-sclerosis","name":"Relapsing multiple sclerosis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":3,"pipeline_drug_count":0,"trial_count":13},"drugs":{"marketed":[{"drug_id":"humax-cd20","indication_name":"Relapsing multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arzerra","generic_name":"HuMax-CD20","company_name":"Glaxo Grp Ltd","drug_phase":"discontinued","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody","quality_score":null,"revenue":"3198","mechanism":"Arzerra works by binding to the CD20 protein on B cells, marking them for destruction by the immune system."},{"drug_id":"dimethyl-fumarate","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tecfidera","generic_name":"DIMETHYL FUMARATE","company_name":"Biogen","drug_phase":"marketed","molecular_target":"Hydroxycarboxylic acid receptor 2","drug_class":"dimethyl fumarate","quality_score":59,"revenue":"2800","mechanism":"Tecfidera works by activating the hydroxycarboxylic acid receptor 2, which helps to reduce inflammation and modulate the immune system."},{"drug_id":"teriflunomide","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aubagio","generic_name":"TERIFLUNOMIDE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"dihydroorotate dehydrogenase","drug_class":"Pyrimidine Synthesis Inhibitor [EPC]","quality_score":75,"revenue":"1100","mechanism":"Teriflunomide inhibits dihydroorotate dehydrogenase, reducing activated lymphocytes in the CNS."},{"drug_id":"siponimod","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mayzent","generic_name":"SIPONIMOD","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate receptor 1","drug_class":"Sphingosine 1-phosphate Receptor Modulator [EPC]","quality_score":10,"revenue":"1068","mechanism":"Mayzent works by binding to the sphingosine 1-phosphate receptor 1, which helps to reduce inflammation and slow disease progression."},{"drug_id":"interferon-beta-1a","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avonex","generic_name":"INTERFERON BETA-1A","company_name":"Biogen","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"Interferon beta [EPC]","quality_score":55,"revenue":"800","mechanism":"Avonex works by binding to the interferon alpha/beta receptor, which helps to reduce inflammation and slow disease progression in multiple sclerosis."},{"drug_id":"ozanimod","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zeposia","generic_name":"OZANIMOD","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate receptor 1","drug_class":"Sphingosine 1-phosphate Receptor Modulator","quality_score":72,"revenue":"800","mechanism":"Zeposia works by binding to the sphingosine 1-phosphate receptor 1, which helps to reduce inflammation and slow disease progression."},{"drug_id":"peginterferon-beta-1a","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Plegridy","generic_name":"PEGINTERFERON BETA-1A","company_name":"Biogen Idec Inc","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"Interferon beta [EPC]","quality_score":10,"revenue":"800","mechanism":"Plegridy works by binding to the interferon alpha/beta receptor, which helps to reduce inflammation and slow disease progression in multiple sclerosis."},{"drug_id":"cladribine","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Leustatin","generic_name":"CLADRIBINE","company_name":"","drug_phase":"marketed","molecular_target":"cAMP-specific 3',5'-cyclic phosphodiesterase 4A","drug_class":"Purine Antimetabolite [EPC]","quality_score":75,"revenue":"700","mechanism":"Leustatin works by inhibiting the enzyme that breaks down cyclic adenosine monophosphate (cAMP), leading to an accumulation of cAMP and subsequent activation of various cellular pathways."},{"drug_id":"diroximel-fumarate","indication_name":"Relapsing Forms of Multiple Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vumerity","generic_name":"DIROXIMEL FUMARATE","company_name":"Biogen","drug_phase":"marketed","molecular_target":"Hydroxycarboxylic acid receptor 2","drug_class":"","quality_score":71,"revenue":"500","mechanism":"Vumerity works by binding to the hydroxycarboxylic acid receptor 2, which helps to reduce inflammation in the central nervous system."},{"drug_id":"diroximel-fumarate","indication_name":"Relapsing forms of multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vumerity","generic_name":"DIROXIMEL FUMARATE","company_name":"Biogen","drug_phase":"marketed","molecular_target":"Hydroxycarboxylic acid receptor 2","drug_class":"","quality_score":71,"revenue":"500","mechanism":"Vumerity works by binding to the hydroxycarboxylic acid receptor 2, which helps to reduce inflammation in the central nervous system."},{"drug_id":"fingolimod","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gilenya","generic_name":"FINGOLIMOD","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate receptor 1","drug_class":"Sphingosine 1-phosphate Receptor Modulator","quality_score":75,"revenue":null,"mechanism":"Gilenya works by binding to and blocking the S1P1 receptor, preventing immune cells from leaving the lymph nodes and reducing inflammation in the central nervous system."},{"drug_id":"alemtuzumab","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Campath","generic_name":"ALEMTUZUMAB","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"CAMPATH-1 antigen","drug_class":"CD52-directed Cytolytic Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Campath works by binding to a specific protein on the surface of immune cells, marking them for destruction."},{"drug_id":"fty720","indication_name":"Treatment of relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FTY720","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)","drug_class":"Sphingosine-1-phosphate receptor modulator; Immunomodulator","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"daclizumab","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zenapax","generic_name":"DACLIZUMAB","company_name":"Hoffman-La Roche","drug_phase":"marketed","molecular_target":"Interleukin-2 receptor","drug_class":"Interleukin-2 Receptor Blocking Antibody","quality_score":21,"revenue":null,"mechanism":""},{"drug_id":"avonex","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avonex","company_name":"Biogen","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"gilenya","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Gilenya","company_name":"University of Southern California","drug_phase":"marketed","molecular_target":"Sphingosine-1-phosphate lyase 1, Sphingosine 1-phosphate receptor 1, Sphingosine 1-phosphate receptor 3","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"plegridy","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Plegridy","company_name":"Holy Name Medical Center, Inc.","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"arzerra","indication_name":"Relapsing multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Arzerra","company_name":"GlaxoSmithKline","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"betaseron","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Betaseron","company_name":"University of Medicine and Dentistry of New Jersey","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"tecfidera","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tecfidera","company_name":"EMD Serono Research & Development Institute, Inc.","drug_phase":"marketed","molecular_target":"Hydroxycarboxylic acid receptor 2, Kelch-like ECH-associated protein 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zenapax","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zenapax","company_name":"National Institute of Neurological Disorders and Stroke (NINDS)","drug_phase":"phase_3","molecular_target":"Interleukin-2 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"mitozantrone","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mitozantrone","company_name":"US Department of Veterans Affairs","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, ATP-binding cassette sub-family G member 2, DNA-(apurinic or apyrimidinic site) lyase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"fingolimod-hydrochloride","indication_name":"Relapsing Forms of Multiple Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FINGOLIMOD HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"laquinimod","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nerventra","generic_name":"LAQUINIMOD","company_name":"Teva","drug_phase":"discontinued","molecular_target":"","drug_class":"laquinimod","quality_score":null,"revenue":null,"mechanism":"Nerventra works by modulating the immune system to reduce inflammation in the central nervous system."},{"drug_id":"azathioprine","indication_name":"Relapsing multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imuran","generic_name":"AZATHIOPRINE","company_name":"Legacy Pharma","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2","drug_class":"Purine Antimetabolite [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"mayzent","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mayzent","company_name":"Novartis Pharmaceuticals","drug_phase":"discontinued","molecular_target":"Sphingosine 1-phosphate receptor 2, Sphingosine 1-phosphate receptor 1, Sphingosine 1-phosphate receptor 3","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"campath","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Campath","company_name":"National Heart, Lung, and Blood Institute (NHLBI)","drug_phase":"marketed","molecular_target":"CAMPATH-1 antigen","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"interferon-beta-1b","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betaseron","generic_name":"INTERFERON BETA-1B","company_name":"Bayer Healthcare Pharms","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"Interferon beta","quality_score":10,"revenue":null,"mechanism":"Betaseron works by binding to the interferon alpha/beta receptor, which helps to reduce inflammation and slow disease progression in multiple sclerosis."},{"drug_id":"ublituximab-xiiy","indication_name":"Relapsing forms of multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BRIUMVI","generic_name":"UBLITUXIMAB-XIIY","company_name":"TG THERAPEUTICS, INC","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"mitoxantrone","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novantrone","generic_name":"MITOXANTRONE","company_name":"","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase pim-1","drug_class":"Topoisomerase Inhibitor","quality_score":71,"revenue":null,"mechanism":"Novantrone works by interfering with the enzyme topoisomerase, which is necessary for DNA replication and cell division."},{"drug_id":"vumerity","indication_name":"Relapsing forms of multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Vumerity","company_name":"University of Nebraska","drug_phase":"marketed","molecular_target":"Nuclear factor erythroid 2-related factor 2, Hydroxycarboxylic acid receptor 2","drug_class":"","quality_score":16,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":31,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03840928","title":"PatientSpot Formerly Known as ArthritisPower","phase":"","overall_status":"UNKNOWN","enrollment_count":40000,"lead_sponsor_name":"Global Healthy Living Foundation","has_results":false},{"nct_id":"NCT00493298","title":"Tysabri Observational Program","phase":"","overall_status":"COMPLETED","enrollment_count":6620,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT01201356","title":"Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":4125,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03193866","title":"COMparison Between All immunoTherapies for Multiple Sclerosis.","phase":"","overall_status":"COMPLETED","enrollment_count":3526,"lead_sponsor_name":"Karolinska Institutet","has_results":true},{"nct_id":"NCT03302442","title":"Comparison of Oral Molecules Preventing Relapses in Multiple Sclerosis","phase":"","overall_status":"COMPLETED","enrollment_count":3000,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT06372145","title":"A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2500,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT03650114","title":"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1882,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT00835770","title":"BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1736,"lead_sponsor_name":"Biogen","has_results":true},{"nct_id":"NCT01797965","title":"Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1501,"lead_sponsor_name":"Biogen","has_results":true},{"nct_id":"NCT01067521","title":"A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1404,"lead_sponsor_name":"Teva Branded Pharmaceutical Products R&D, Inc.","has_results":true},{"nct_id":"NCT02047734","title":"Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1320,"lead_sponsor_name":"Celgene","has_results":true},{"nct_id":"NCT02230969","title":"Plegridy Observational Program","phase":"","overall_status":"COMPLETED","enrollment_count":1208,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT04338061","title":"Study of Evobrutinib in Participants With RMS (evolutionRMS 2)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1166,"lead_sponsor_name":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","has_results":true},{"nct_id":"NCT04411641","title":"Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1131,"lead_sponsor_name":"Sanofi","has_results":true},{"nct_id":"NCT04338022","title":"Study of Evobrutinib in Participants With RMS (evolutionRMS 1)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1124,"lead_sponsor_name":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","has_results":true},{"nct_id":"NCT01930708","title":"A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1114,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT04130997","title":"An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1100,"lead_sponsor_name":"TG Therapeutics, Inc.","has_results":false},{"nct_id":"NCT01633112","title":"MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1064,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02255656","title":"Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1062,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":true},{"nct_id":"NCT01047319","title":"A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1047,"lead_sponsor_name":"Teva Branded Pharmaceutical Products R&D, Inc.","has_results":true},{"nct_id":"NCT05156281","title":"Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1011,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05147220","title":"Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1001,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04031469","title":"A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease","phase":"","overall_status":"SUSPENDED","enrollment_count":1000,"lead_sponsor_name":"ProgenaBiome","has_results":false},{"nct_id":"NCT05204459","title":"MS-ResearchBiomarkerS","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Cedars-Sinai Medical Center","has_results":false},{"nct_id":"NCT04410978","title":"Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":974,"lead_sponsor_name":"Sanofi","has_results":true},{"nct_id":"NCT02792218","title":"Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":930,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT04410991","title":"Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":899,"lead_sponsor_name":"Sanofi","has_results":true},{"nct_id":"NCT01623596","title":"Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":881,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT00641537","title":"CLARITY Extension Study","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":867,"lead_sponsor_name":"EMD Serono Research & Development Institute, Inc.","has_results":true},{"nct_id":"NCT00988052","title":"A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":839,"lead_sponsor_name":"Teva Branded Pharmaceutical Products R&D, Inc.","has_results":true},{"nct_id":"NCT01412333","title":"A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":835,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT01247324","title":"A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":821,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT05344469","title":"A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05877963","title":"Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"TG Therapeutics, Inc.","has_results":false},{"nct_id":"NCT00078338","title":"Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":764,"lead_sponsor_name":"EMD Serono","has_results":true},{"nct_id":"NCT04586023","title":"Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":751,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT04586010","title":"A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":746,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT04688788","title":"Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT02921035","title":"Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS)","phase":"","overall_status":"COMPLETED","enrollment_count":594,"lead_sponsor_name":"Merck KGaA, Darmstadt, Germany","has_results":false},{"nct_id":"NCT04353492","title":"An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":562,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03277261","title":"Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":549,"lead_sponsor_name":"TG Therapeutics, Inc.","has_results":true},{"nct_id":"NCT03277248","title":"Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":545,"lead_sponsor_name":"TG Therapeutics, Inc.","has_results":true},{"nct_id":"NCT03093324","title":"A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":506,"lead_sponsor_name":"Biogen","has_results":true},{"nct_id":"NCT06433752","title":"A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"TG Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05949580","title":"Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT06700343","title":"Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":444,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT01051349","title":"Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":410,"lead_sponsor_name":"Biogen","has_results":true},{"nct_id":"NCT05758831","title":"RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":386,"lead_sponsor_name":"Rennes University Hospital","has_results":false},{"nct_id":"NCT03257358","title":"A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":382,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT04928313","title":"Safety and Effectiveness of Cinnomer® (Glatiramer Acetate) in Multiple Sclerosis (MS) Treatment in Iran","phase":"","overall_status":"COMPLETED","enrollment_count":368,"lead_sponsor_name":"Cinnagen","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}